Figure S2 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies

Supplementary Fig. S2. The in vitro antitumor activity of ADCT-602 does not correlate with CD22 levels in B-cell lymphomas. This figure shows a correlation of ADCT-602 IC50 values versus (A) cell surface protein expression via absolute fluorescence quantitation with Quantum Simply Cellular microspheres, (B) CD22 RNA expression levels measured via Illumina HT-12 microarrays, and (C) targeted RNA-Seq with the HTG EdgeSeq Oncology Biomarker Panel. On each plot, the x-axes are the ADCT-602 IC50 values presented as log2, and the y-axes are CD22 expression levels presented as log2. Cell lines derived from Hodgkin and T-cell lymphomas have been excluded. IC50 50% inhibitory concentration.